Wijziging van de Wet geneesmiddelenprijzen in verband met een aanpassing van de referentielanden

This motion proposes an amendment to the Medicines Prices Act. The goal is to update the list of reference countries used to determine the maximum prices for pharmaceutical products in the Netherlands, ensuring that pricing remains aligned with current market standards. This change primarily affects pharmaceutical companies and healthcare payers by altering how drug prices are calculated and benchmarked against other EU member states.